Genome-wide analysis of blood lipid metabolites in over 5000 South Asians reveals biological insights at cardiometabolic disease loci. by Harshfield, Eric L et al.
RESEARCH ARTICLE Open Access
Genome-wide analysis of blood lipid
metabolites in over 5000 South Asians
reveals biological insights at
cardiometabolic disease loci
Eric L. Harshfield1,2*, Eric B. Fauman3, David Stacey1, Dirk S. Paul1,4,5,6,7,8, Daniel Ziemek9, Rachel M. Y. Ong1,
John Danesh1,4,5,6,7,8, Adam S. Butterworth1,4,5,6,7,8, Asif Rasheed10, Taniya Sattar10, Zameer-ul-Asar10,
Imran Saleem10, Zoubia Hina10, Unzila Ishtiaq10, Nadeem Qamar11, Nadeem Hayat Mallick12, Zia Yaqub11,
Tahir Saghir11, Syed Nadeem Hasan Rizvi11, Anis Memon11, Mohammad Ishaq13, Syed Zahed Rasheed13,
Fazal-ur-Rehman Memon14, Anjum Jalal15, Shahid Abbas15, Philippe Frossard10, Danish Saleheen10,16†,
Angela M. Wood1,4,5,6,7,8†, Julian L. Griffin17,18*† and Albert Koulman19*†
Abstract
Background: Genetic, lifestyle, and environmental factors can lead to perturbations in circulating lipid levels and
increase the risk of cardiovascular and metabolic diseases. However, how changes in individual lipid species
contribute to disease risk is often unclear. Moreover, little is known about the role of lipids on cardiovascular
disease in Pakistan, a population historically underrepresented in cardiovascular studies.
Methods: We characterised the genetic architecture of the human blood lipidome in 5662 hospital controls from
the Pakistan Risk of Myocardial Infarction Study (PROMIS) and 13,814 healthy British blood donors from the
INTERVAL study. We applied a candidate causal gene prioritisation tool to link the genetic variants associated with
each lipid to the most likely causal genes, and Gaussian Graphical Modelling network analysis to identify and
illustrate relationships between lipids and genetic loci.
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Results: We identified 253 genetic associations with 181 lipids measured using direct infusion high-resolution mass
spectrometry in PROMIS, and 502 genetic associations with 244 lipids in INTERVAL. Our analyses revealed new
biological insights at genetic loci associated with cardiometabolic diseases, including novel lipid associations at the
LPL, MBOAT7, LIPC, APOE-C1-C2-C4, SGPP1, and SPTLC3 loci.
Conclusions: Our findings, generated using a distinctive lipidomics platform in an understudied South Asian
population, strengthen and expand the knowledge base of the genetic determinants of lipids and their association
with cardiometabolic disease-related loci.
Keywords: Lipidomics, Genetics, Gaussian Graphical Modelling, Network analysis, South Asian
Background
Mass spectrometry-based lipidomics, which aims to
capture information on the full complement of lipid
metabolites in a given biological sample [1], holds the
potential to identify novel insights leading to lipid
regulation and dyslipidaemia, potentially providing
new mechanisms that link lipid perturbances with
cardiometabolic disorders. While pathways underlying
dyslipidaemia have been widely studied, we still do
not understand how individual lipid species are regu-
lated or contribute to disease. With increasing rates
of cardiometabolic diseases in low- and middle-
income countries, there is a need for well-powered
studies to understand the mechanisms that lead to
such disorders in these settings. This need is espe-
cially acute for genetic studies where the overrepre-
sentation of individuals of European ancestry amongst
genotyped cohorts has led to ancestral bias in effect
size estimates at both the genotype and polygenic
score levels [2].
In this study, we aimed to identify novel genetic
associations with lipid metabolites in an understud-
ied South Asian population and determine plausible
metabolic pathways for the significantly associated
lipid metabolites. We performed a comprehensive in-
terrogation of genetic influences on the human
blood serum lipidome using direct infusion high-
resolution mass spectrometry (DIHRMS). We quanti-
fied 340 lipid metabolites in 5662 individuals from
Pakistan, from which we identified 253 genotype–
lipid associations (lipid quantitative trait loci, or lipid
QTLs [3, 4]) at 24 independent loci, providing new
insights into lipid metabolism and its impact on car-
diovascular and metabolic diseases.
To help disentangle which of these findings are
specific to the Pakistani population and which are
unique to the lipid platform itself, we also carried
out a parallel set of analyses using the same lipido-
mics platform in a much larger cohort of individuals
from the UK. We measured 399 lipid metabolites in
13,814 healthy British blood donors, from which we
identified 502 lipid QTLs at 38 independent loci.
Methods
Study descriptions
Our primary analyses involved a subset of participants
from the Pakistan Risk of Myocardial Infarction Study
(PROMIS), a case-control study of first-ever acute myo-
cardial infarction (MI) in nine urban centres in Pakistan
consisting of approximately 16,700 cases and 18,600
controls. Details of PROMIS have been described previ-
ously [5]. In this analysis, we analysed controls (individ-
uals free from MI at baseline), who were identified and
recruited at the same hospitals as cases according to the
following order of priority: (1) visitors of patients attend-
ing the outpatient department, (2) patients attending
outpatient clinics for non-cardiac-related symptoms, and
(3) non-first-degree relative visitors of MI cases. The
present analysis involved serum samples from 5662
PROMIS controls for which genetic and lipid-profiling
data were available. Ethical approval was obtained from
the relevant ethics committee of each of the institutions
involved in participant recruitment and the Center for
Non-Communicable Diseases in Karachi, Pakistan, and
informed consent was obtained from each participant re-
cruited into the study, including for use of samples in
genetic, biochemical, and other analyses.
Comparative, parallel analyses were performed in
INTERVAL, a prospective cohort study of approximately
50,000 healthy blood donors from the UK, the details of
which have been described previously [6]. In this study,
we analysed data from 13,814 participants with genetic
and lipid-profiling data.
Lipid profiling
Lipid levels in human serum were quantified using direct
infusion high-resolution mass spectrometry (DIHRMS),
as we described previously [7]. In brief, we extracted
lipids from the serum samples using an Anachem Flexus
automated liquid handler (Anachem, Milton Keynes,
UK) and transferred the samples to 96-well plates using
a 96-head microdispenser (Hydra Matrix, Thermo Fisher
Ltd., Hemel Hampstead, UK). We then used a Triversa
Nanomate (Advion, Ithaca, USA) to infuse the samples
into an Exactive Orbitrap (Thermo, Hemel Hampstead,
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UK), which acquired the lipid signal data. Data process-
ing, peak-picking, normalisation, cleaning, and quality
control were performed to identify and record signals
for 340 known lipids in 5662 PROMIS participants. The
340 lipids corresponded to five broad lipid categories
(fatty acyls and derivatives, glycerolipids, glyceropho-
spholipids, sphingolipids, and sterol lipids), which are
further subdivided into fourteen lipid subclasses (Supple-
mentary Table 3 in Additional file 2). Our peak-picking
algorithm [7] selected all lipids within an m/z window of
185–1000, using a time window of 20–70 s for lipids in
positive ionisation mode and 95–145 s for lipids in nega-
tive ionisation mode. A lipid list containing all known
lipids within this m/z range was used to extract informa-
tion on the lipid concentrations at specific peaks of
interest, consisting of 1305 lipids in positive ionisation
mode and 3772 lipids in negative ionisation mode. Qual-
ity control samples and blanks were used to remove
lipids that were not able to be detected or had poor
quality of assessment, resulting in a final list of 340 dis-
tinct lipid annotations across both ionisation modes. We
normalised each lipid by expressing the intensity as a
proportion of the total signal for each participant and
then applied a log transformation to obtain an approxi-
mately normal distribution.
We performed DIHRMS on INTERVAL participants
using the same protocol. We obtained data on 399 lipids,
228 in positive ionisation mode, and 171 in negative ion-
isation mode, which make up 19 lipid subclasses (Sup-
plementary Table 1).
Genotyping and imputation
DNA from PROMIS participants was extracted from
leukocytes in Pakistan and genotyped at the Wellcome
Sanger Institute in Cambridge, UK, on either (1) the Illu-
mina 660-Quad GWAS platform, which consisted of
527,925 genotyped autosomal variants after quality con-
trol (QC) steps were performed, or (2) the Illumina
HumanOmniExpress GWAS platform, which consisted
of 643,333 genotyped autosomal variants after QC. Gen-
etic samples were removed if (1) they were heterozygos-
ity outliers (heterozygosity > mean ± 3 SD), (2) the
sample call rate was less than 97%, (3) there was dis-
cordant sex between genetically inferred and self-
reported sex, or (4) they were duplicate or related pairs
(kinship coefficient > 0.375). Single nucleotide polymor-
phisms (SNPs) were excluded if (1) the SNP call rate
was less than 97%, (2) there was evidence of departure
from Hardy-Weinberg Equilibrium (HWE) at a P value
of less than 1 x 10-7, or (3) the minor allele frequency
(MAF) was less than 1%. Imputation was applied to the
cleaned PROMIS datasets using the 1000 Genomes Pro-
ject March 2012 (v3) release [8] as the reference panel.
Imputation was conducted using IMPUTE v2.1.0 [9]
using 5-Mb non-overlapping intervals for the whole gen-
ome. Once imputation had been performed for the sam-
ples on both genotyping platforms separately, there were
over 7.2 million imputed SNPs available for analyses in
either dataset before further QC. SNPs were removed if
they were poorly imputed, i.e., if they had an information
score (an assessment of the level of accuracy of imput-
ation) < 80%. The results were then extracted from the
output files, and once the final QC filters were reapplied,
6,720,657 SNPs were available for analyses of the lipido-
mics data. In total, 5662 individuals from PROMIS had
concomitant information on lipidomics data and im-
puted SNPs.
DNA from INTERVAL participants was extracted
from buffy coat at LGC Genomics (UK) using a Klear-
gene method, and samples of sufficient concentration
and purity were aliquoted for shipment to Affymetrix for
genotyping [10]. Duplicate samples and samples that
were not of European ancestry were excluded. Addition-
ally, SNPs were excluded if (1) the variant had fewer
than 10 called minor allele homozygotes, (2) the cluster
plot contained at least one sample with an intensity at
least twice as far from the origin as the next most ex-
treme sample, (3) the outlying sample(s) had an extreme
polar angle (<15° or >75°) in the direction of the minor
allele, (4) call rate < 99% per batch and < 75% overall,
(5) MAF < 0.05, (6) HWE P < 1 x 10-6, or (7) r2 ≥ 0.2 be-
tween pairs of variants [10]. The dataset was phased
using SHAPEIT3 (in chunks of 5000 variants with an
overlap of 250 variants between chunks) and subse-
quently imputed using the 1000 Genomes Phase 3-
UK10K imputation panel, resulting in 87,696,910 im-
puted variants in the dataset [10]. In total, 13,814 indi-
viduals from INTERVAL had overlapping information
on lipidomics data and imputed SNPs.
Primary genome-wide association analyses
In PROMIS, linear regression was used to determine the
association of each lipid with each SNP using SNPTEST
v2.4.1 [11], which was performed separately for the sam-
ples genotyped on each of the two genetic platforms. Re-
siduals were calculated from the null model for each
lipid, which included adjustment for age group, sex, date
of survey, plate (batch), and fasting status. To account
for population stratification and genetic substructure in
the data, principal component analysis was conducted
on the multi-dimensional scaling matrix created from
autosomal SNPs as implemented in PLINK; the first six
principal components were subsequently added to each
model. A missing data likelihood score test was used
when testing for association at imputed SNPs to account
for genotype uncertainty. Beta estimates and standard
errors from the association results for the two genetic
platforms were combined in a fixed-effect inverse-
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variance-weighted meta-analysis using METAL version
2011-03-25 [12]. The threshold for genome-wide signifi-
cance level was set to P < 8.929 x 10-10, which corrected
for multiple testing by dividing the standard genome-
wide significance level (5 x 10-8) by the number of prin-
cipal components (56) that explained over 95% of the
variance in the levels of the lipids. All traits gave gen-
omic inflation factors (λ) in the meta-analysis less than
1.05 [mean (SD) 1.0139 (0.0129); range 0.9741–1.0455],
indicating that there was little evidence of systematic
bias in the test statistics.
To verify the robustness and validity of the results,
post-analysis quality control (QC) was performed by
comparing the meta-analysis results with the results on
each GWAS platform. The lead SNPs from the meta-
analysis were only kept if they (1) passed QC in the raw
SNPTEST results from both GWAS platforms (i.e. HWE
P < 1 x 10-7, call rate < 0.97, MAF < 0.01, and info score
< 0.80); (2) had beta (β) estimates in the same direction
on both platforms (i.e. betas were both negative or both
positive); and (3) had P < 0.01 on both platforms (with P
< 8.9 x 10-10 in the meta-analysis).
In INTERVAL, linear regression was performed using
BOLT-LMM v2.2 [13] to determine the association of
each lipid with each SNP. Residuals were calculated
from the null model for each lipid with adjustment for
plate, age, sex, centre, appointment month, appointment
hour, processing time in hours, and the first three gen-
etic principal components. The threshold for genome-
wide significance level was set to P < 4.464 x 10-10 (5 x
10-8/112), as 112 principal components explained >95%
of the variance in lipid levels.
Genome-wide analysis of ratios of lipids
A second discovery step was carried out in PROMIS by
testing genome-wide associations on 26 pairwise ratios
of lipid concentrations. Ratios were identified based on
those that had strong biological rationales and that acted
through thoroughly understood metabolic pathways (list
of ratios with rationales and references provided in Sup-
plementary Table 7). Meta-analysis was performed to
combine results from the two genotyping platforms
using a fixed-effect inverse-variance weighted meta-
analysis. Since there were fewer statistical tests for the
ratios than for the individual lipids, the combined result
file for each ratio was filtered using the standard thresh-
old for genome-wide significance of P < 5 x 10-8.
Conditional analyses
We conducted conditional analyses on the significant
loci from the meta-analysis results of the univariate
GWAS for each lipid in PROMIS. All SNPs were se-
lected where P < 8.9 x 10-10, the 5-Mb chunks were
identified where each of these SNPs were located, and
the lead SNPs were selected within each chunk that had
the strongest P value. On an individual lipid basis, for
each 5-Mb chunk that was identified, SNPTEST was run
on the imputed data for each genotyping platform using
the same null model as before, except also conditioning
on the lead SNP in the identified chunk. The results
from the samples analysed on each genotyping platform
were combined in a meta-analysis using METAL as de-
scribed above, and any SNPs where P < 8.9 x 10-10 were
identified. The lead SNP from the meta-analysed results
of the first conditional analysis (i.e. the SNP with the
strongest P value) was identified, and this process was
repeated for each chunk. Additional SNPs to be condi-
tioned on were repeatedly added to the model on each
chunk for each lipid until there were no more significant
SNPs left within that chunk. The final set of SNPs that
were “conditionally independent” for each lipid were
combined into a single list across all lipids, resulting in
253 SNP-lipid associations (lipid QTLs) for 181 lipids, or
90 unique lead SNPs. These variants were grouped into
24 loci using a distance measure of ±500 Kb.
We identified the proportion of variation in the lipi-
dome explained by inherited genetic variants by regres-
sing each lipid on the number of copies of each allele
held by each participant for each of the conditional ana-
lysis sentinel SNPs.
As a sensitivity analysis, we also conducted a GWAS
for all significant lipids from the conditional analyses
using the same regression models with additional adjust-
ment for several clinical lipid measures (total cholesterol,
HDL-C, and triglycerides).
Candidate gene annotation
In order to prioritise candidate genes that might under-
pin the genotype—lipid associations, we applied the Pro-
GeM framework (Supplementary Figure 6 in Additional
file 1) to both PROMIS and INTERVAL [14]. In addition
to reporting the nearest gene to the sentinel variant,
ProGeM combines information from complementary
“bottom-up” and “top-down” approaches to assess the
credibility of potential candidate genes [14] (Supplemen-
tary Table 9).
For the bottom-up approach, we annotated SNPs
based on their putative effects on proximal gene func-
tion if any of the following conditions were met: (1) the
SNP resided within an exonic sequence of a gene (Sup-
plementary Table 9), (2) the SNP resided within a splice-
site (±2 bp from an intron-exon boundary), (3) the SNP
was in high linkage disequilibrium (LD) (r2 ≥ 0.8) with a
non-synonymous SNP (Supplementary Table 10), and/or
(4) the SNP was a cis-eQTL for a local gene (Supple-
mentary Table 11). To identify any exonic and splice site
SNPs within our SNP list, we ran the Variant Effect Pre-
dictor (VEP) (http://www.ensembl.org/common/Tools/
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VEP?db=core) on the list of variants with the “pick” op-
tion (which outputs one block of annotation per variant)
and used Ensembl transcripts as the reference for deter-
mining consequences. SNPs in high LD with our list of
associated SNPs were identified within our imputed
dataset and run through VEP to select only non-
synonymous SNPs. Cis-eQTLs within our list of associ-
ated SNPs were identified using eQTL data provided by
the Genotype-Tissue Expression (GTEx) project (http://
www.gtexportal.org/home/datasets), keeping only signifi-
cant SNP-gene associations (filename: “GTEx_Analysis_
v7_eQTL.tar.gz”). We only annotated SNPs if they were
significant eQTLs in at least one of the following tissues
we deemed most relevant for lipid-related phenotypes:
subcutaneous adipose tissue, visceral adipose tissue,
liver, and/or whole blood.
In the top-down approach, for each of our associated
SNPs, we first identified all proximal genes located ≤
500-Kb upstream or downstream using the ANNOVAR
tool (http://annovar.openbioinformatics.org/en/latest/).
We then identified all genes previously associated with a
lipid-related biological process or function from the fol-
lowing databases: (1) LIPID MAPS Proteome Database
(LMPD) (http://www.lipidmaps.org/data/proteome/
LMPD.php) , (2 ) Gene Onto logy (GO) (ht tp : / /
geneontology.org/), (3) Online Mendelian Inheritance in
Man catalogue (OMIM), (4) Mouse Genome Informatics
(MGI) database (http://www.informatics.jax.org/), (5)
Kyoto Encyclopedia of Genes and Genomes (KEGG)
(http://www.genome.jp/kegg/), and/or (6) Ingenuity
Pathway Analysis (IPA) (http://www.ingenuity.com/
products/ipa).
LMPD is an object-relational database of lipid-
associated genes and proteins across multiple species in-
cluding human, mouse, and fruit fly; we simply extracted
all human genes (1116 genes in total) from this database
(accessed 16-Mar-2016). For GO and OMIM, we first
identified all terms or Mendelian diseases containing
one or more lipid-related keyword(s) using HumanMine
(http://www.humanmine.org/), then we extracted all hu-
man genes associated with one or more of these terms
(accessed 01-Apr-2016 and 07-Apr-2016). Similarly, for
MGI we extracted all mouse genes using MouseMine
(http://www.mousemine.org/mousemine/begin.do)
(accessed 31-Mar-2016) that were associated with the
following manually selected lipid-related terms and their
children: (1) abnormal lipid homeostasis (MP:0002118),
(2) abnormal lipoprotein level (MP:0010329), (3) abnor-
mal lipid metabolism (MP:0013245), and (4) adipose tis-
sue phenotype (MP:0005375). From the KEGG database,
we extracted all lipid compounds (with “C” number IDs)
with biological roles in order to identify all genes associ-
ated with reactions (with “R” number IDs) involved in
lipid biology using MitoMiner (http://mitominer.mrc-
mbu.cam.ac.uk/release-3.1/begin.do) (accessed 31-Mar-
2016). Finally, from IPA, we downloaded the interaction
networks for all fourteen of the lipid subclasses in order
to extract all genes in a compound-specific manner
(accessed 13-Apr-2016).
Once we had obtained lists of lipid-related genes from
the aforementioned databases, we then searched for
overlap with our list of proximal (≤ 500 Kb) genes based
on HUGO Gene Nomenclature Committee (HGNC)
symbols, thereby annotating SNPs with proximal genes
where there was evidence that at least one might be in-
volved in lipid-related biology. For each lead SNP, we
first recorded whether there was any compound-specific
evidence from IPA for a SNP-gene assignment whereby
both the SNP (from this study) and the gene (from IPA)
were associated with the same lipid subclass. Then, from
the five remaining (compound non-specific) databases,
we categorised overlapping genes as either (1) recurrent
candidates, in that they were highlighted in at least two
different databases, or (2) single candidates. Further, we
assigned the recurrent candidates a score out of five for
prioritisation purposes, with one point awarded for each
database highlighting them as being lipid-related.
After performing comprehensive annotation of SNPs
as per the bottom-up and top-down procedures, we then
integrated this information to try to predict the most
likely causal gene(s) using a hierarchical approach as fol-
lows: (1) For those lead SNPs where the same gene was
highlighted by both the bottom-up and the top-down
approach, we selected this gene as the putative causal
gene; (2) If both the SNP (from this study) and the prox-
imal gene (from IPA) were associated with the same
lipid subclass, we made further SNP-gene assignments
accordingly; (3) finally, for each of the remaining lead
SNPs, we assigned the highest scoring top-down gene
and any bottom-up genes as the likely causal gene(s).
Separately, we assigned an expertly curated causal
gene to each variant and compared the predicted causal
genes identified by the functional annotation pipeline to
assess concordance and validate the pipeline.
Gaussian Graphical Modelling
As described previously [7], we estimated a Gaussian
Graphical Model (GGM) on the normalised relative in-
tensities of the lipids in PROMIS to better resolve lipid
cross-correlations. The GGM resulted in a set of edges
in which each edge connected two detected lipids if their
cross-correlation conditioned on all other lipids was sig-
nificantly different from zero. Subjects with more than
10% missing lipids as well as lipids with more than 20%
missing subjects were removed from the analysis. The
“genenet” R package was used to infer the GGM [15]. A
similar approach for metabolomics data has been sug-
gested previously [16]. To focus on strong effects, we
Harshfield et al. BMC Medicine          (2021) 19:232 Page 5 of 17
retained only edges in the model that met an FDR cutoff
of 0.05 and had a partial correlation coefficient greater
than 0.2.
Fatty acid chain enrichment analysis
We manually annotated detected lipids in PROMIS with
their constituent fatty acid chains. For each combination
of fatty acid chains, we counted the number of GGM
edges connecting lipids with that specific combination,
which we used to directly estimate P values of enrich-
ment and depletion. To test whether edges from the
GGM were enriched for any combination of fatty acid
chains, we permuted the annotation 1000 times using
the R package “BiRewire” [17], keeping the number of
annotations per lipid and fatty acid chain constant.
Network of genetic and metabolic associations
We used Cytoscape v3.2.1 [18] to generate a network of
associations between genes and lipid subclasses in PRO-
MIS (Fig. 3). Using a previously described approach [19],
we constructed a GGM to connect lipids to each other
based on partial correlation coefficients, and we also
connected lipids with genetic loci using the conditional
analysis results, with one link for each genome-wide sig-
nificant association. The full network facilitates visualisa-
tion of the genetic determinants of human metabolism
and the relationships between genetic loci and lipid
subclasses.
The network diagrams were created by combining two
parts to integrate different sources of information. The
first part was created by loading the reported associa-
tions between lipids and genes into Cytoscape. Lipid
species were clustered according to the lipid subclass
they belong to, resulting in fourteen distinct lipid sub-
class nodes in the network. The 90 identified lead SNPs
from the conditional analyses were clustered according
to their corresponding predicted causal gene(s), which
was determined using the ProGeM framework [14]. In
cases where it was not possible to confidently identify a
single predicted causal gene, loci were entered into the
network instead. For the second part, a functional inter-
action network consisting solely of our list of predicted
causal genes/loci was created in Cytoscape using inter-
action network data downloaded from IPA that had
been merged using in-house R scripts to create a .sif file.
For loci with multiple potential causal genes, interaction
networks for all genes were extracted from IPA and an
edge was drawn if at least one gene at that locus func-
tionally interacts with another of our lipid-associated
genes according to IPA. Finally, these two parts were
merged together by node names (i.e. gene symbols). No
enrichment statistics (e.g. KEGG pathways or GO terms)
or other statistical information was used to produce the
network, since this information was already incorporated
to inform the predictions of the most likely “causal”
genes, and would therefore invalidate the conclusions if
it was also used to inform the network.
A second network diagram was created containing a
subset of the first network containing only the triglycer-
ide species (Fig. 4). It also provides more detail as it
shows the individual triglycerides rather than the lipid
subclass as a whole. Thus, it portrays the partial correla-
tions of the triglycerides with each other and the associ-
ation of each triglyceride with genetic loci.
Results
Genetic architecture of the lipidome in South Asians and
in the UK
We performed a genome-wide association study
(GWAS) on the levels of 340 lipid metabolites using 6.7
million imputed autosomal variants in 5662 hospital-
based controls from PROMIS. We applied DIHRMS to
quantify serum lipid metabolites across five broad lipid
categories, i.e. fatty acyls and derivatives, glycerolipids,
glycerophospholipids, sphingolipids, and sterol lipids [7].
We demonstrated the robustness of these lipid measure-
ments in several ways, including validation of lipid sig-
nals against blanks, pooled samples, and internal
standards, with a median coefficient of variation of
11.60% (range 5.4–51.9), as we described previously [7].
Additionally, we replicated known associations of lipid
metabolites with previously reported major lipid loci
(Supplementary Table 17). After Bonferroni correction
for multiple testing of variants and lipid metabolites (P <
8.929 × 10-10), we found 253 significant associations be-
tween 181 lipid metabolites and 24 genomic regions
(Figs. 1 and 2, Supplementary Figure 1, Supplementary
Table 4). The majority of these lipid metabolites (67%; n
= 171) were associated with variation at a single locus,
while 26% of lipid metabolites were associated with two
loci and 7% were associated with three or more loci
(Supplementary Figures 2a and 3). To detect multiple in-
dependent associations at the same locus, we used step-
wise conditional analysis, identifying 90 conditionally
independent variants associated with lipid metabolites
(Supplementary Table 5). 335 (93%) of the lipid QTLs
had multiple conditionally significant associations (Sup-
plementary Figure 2b).
Using the same DIHRMS platform, we also performed
a GWAS on levels of 399 lipid metabolites using 87.7
million imputed autosomal variants in 13,814 British
blood donors from INTERVAL. We identified significant
associations with lipids at 38 independent loci (Fig. 1,
Supplementary Table 6). There was considerable
consistency in the genomic regions identified in each
study, with 18 (75%) of the significant genetic loci from
PROMIS also found in INTERVAL (Fig. 1). Six genetic
loci were specific to lipid levels in the Pakastani
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population: ANGPTL3, UGT8, PCTP, C19orf80, XBP1,
and GAL3ST1. There were also twenty genetic loci asso-
ciated with lipids in the British population that were not
significantly associated with lipids in the Pakistani popu-
lation. The beta estimates were consistent in magnitude
and direction in both studies (Pearson correlation r=
Fig. 1 Miami plot of combined association results from genome-wide association analysis for all lipids in PROMIS and INTERVAL. The combined
association results are shown for all lipids with each variant in PROMIS (top) and INTERVAL (bottom). P values > 1 x 10-3 have been truncated at 1
x 10-3, and P values < 1 x 10-200 have been truncated at 1 x 10-200. Actual P value for lead SNP in FADS-1-2-3 locus in INTERVAL is 1.6 x 10-286
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Fig. 2 (See legend on next page.)
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0.92), and the P values also showed consistency between
studies (Supplementary Figure 3).
In PROMIS, the median proportion of variation in the
lipidome explained by the genome-wide significant con-
ditionally independent variants was 1.7% (interquartile
range 1.5–1.9%) (Supplementary Figure 2c), which is
slightly less than that reported in metabolomics studies
[19–22] but similar to the reported variation explained
in previous lipidomics studies [23, 24]. There was a
strong inverse relationship between effect size and minor
allele frequency (MAF) (Supplementary Figure 2d), con-
sistent with previous GWAS of quantitative traits [10,
25]. Approximately 70% of the analysed genetic variants
in this analysis were common (MAF >5%) and 30% were
low-frequency (MAF: 1-5%) with a median MAF of 8%.
To help identify candidate causal genes through which
genetic loci may influence lipid levels and thereby im-
pact disease risk, we applied the ProGeM framework
[14] (Supplementary Tables 9-15, Supplementary Figure
6). We identified a plausible or established link to bio-
chemical function for 16 of the 24 loci (including GCKR,
LPL, FADS1-2-3, and APOA5-C3), involving 34 unique
genes. In cases where it was not possible to annotate
SNPs using our systematic approach, we assigned them
to their nearest protein-coding gene.
Previous studies have shown that the ratios of metabo-
lites can strengthen association signals and lead to a better
understanding of possible mechanisms [19]. Thus, in
addition to the individual lipid metabolites, we selected
twenty-six ratios of lipid metabolites that act through
well-understood metabolic pathways. These included ra-
tios associated with lipase activity, elongases, docosahex-
aenoic acid (DHA) levels, dairy fat intake, insulin
production, glucose control, de novo lipogenesis, and car-
diovascular disease risk (Supplementary Table 7).
Genome-wide association analyses of these ratios in PRO-
MIS resulted in the identification of four additional loci
that were not detected in the GWAS of individual lipid
metabolites (MYCL1-MFSD2A, LPGAT1, LOC100507470,
and HAPLN4-TM6SF1) (Supplementary Table 8).
Since most of the lipid species that we measured are
present in lipoprotein particles, we explored whether the
variance in clinical lipid measures (total cholesterol,
HDL, and triglycerides) are likely to be major drivers of
variation in lipid levels. Adjustment for clinical lipid
measures showed that many associations were independ-
ent of the genetic variant’s effect on clinical lipids, in-
cluding those in the CERS4, CET4, ELOVL2, SCD, and
UGT8 loci, and for lysophosphatidylcholines (Supple-
mentary Table 18, Supplementary Figure 8). However,
several associations (e.g. in the FADS1-2-3, MBOAT7,
and LIPC loci, and for phosphatidylcholines, phosphati-
dylethanolamines, and sphingomyelins) attenuated sub-
stantially upon adjustment, suggesting that the genetic
variants’ effects on specific lipid species are driven by
their effect on clinical lipid measures.
Network of genetic and metabolic associations
To identify and visualise the connectivity between lipid
subclasses, we generated a network of genetic and meta-
bolic associations in PROMIS by summarising within
each subclass the pairwise partial correlations between
lipid metabolites and their genetic associations (Fig. 3).
This network diagram highlights that the number of
connections between diglycerides and triglycerides was
strongly over-represented in the Gaussian Graphical
Model (GGM), indicating that there were more signifi-
cant partial correlations between lipids from these sub-
classes than would be expected due to chance alone,
whereas the number of connections between sphingo-
myelins and triglycerides was strongly under-represented
in the GGM. In addition to being associated with vari-
ants from the SPTLC3 and FADS1-2-3 loci, we found
that sphingomyelins were associated exclusively with
four loci that were not associated with any other lipid
subclasses: GCKR, SGPP1, MLXIPL, and XBP1.
Given the striking findings for triglycerides in the
overall network diagram, we also generated a network in
PROMIS for a subset of the triglyceride species showing
the partial correlations of individual triglycerides and
their detailed associations with genetic loci (Fig. 4). This
network diagram shows that variants in the APOA5-C3
locus are associated with a wide range of triglycerides,
consistent with previous associations of Apolipoprotein
A-V (ApoA5) with plasma triglyceride levels. ApoA5 is a
component of a number of lipoprotein fractions includ-
ing HDL, VLDL, and chylomicrons, and it may regulate
the catabolism of triglyceride-rich lipoprotein particles
by LPL and/or play a role in the assembly of VLDL par-
ticles [26–30]. The network mainly shows links with
(See figure on previous page.)
Fig. 2 Heat map showing associations of significant loci from conditional analyses with selected lipid metabolites in PROMIS. The effect estimates
of the associations between significant variants and selected lipids are plotted as a heat map. Results are shown for selected top lipids with the
strongest associations within each subclass (rows) against the most strongly associated genetic variant within each locus (columns). The
associations with major lipids from the GLGC (total cholesterol, HDL-C, LDL-C, and triglycerides), DIAGRAM Consortium (type 2 diabetes), and
CARDIoGRAMplusC4D Consortium (coronary artery disease) are also shown. The magnitude and direction of the effect estimates (standardised per 1-
SD) are indicated by a colour scale, with blue indicating a negative association and red indicating a positive association with respect to the SNP effect
on the trait. Asterisks indicate the degree of significance of the P values of association. * = P < 1 x 10-4; ** = P < 5 x 10-8; *** = P < 8.9 x 10-10
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triglycerides containing polyunsaturated fatty acids
(PUFAs), suggesting that variants in the APOA5-C3
locus mainly affect the catabolism of lipoproteins con-
taining triglycerides derived from adipose tissues that
are relatively enriched in more unsaturated fatty acids.
In contrast, we did not see direct links of fully saturated
triglycerides with the APOA5-C3 locus, suggesting that
genetic variation at this locus is not particularly involved
in the assembly of VLDL particles in the liver as part of
de novo lipogenesis, in concordance with previous stud-
ies [31, 32] (see Supplementary Figure 5).
Fatty acid desaturase is key in the production of
PUFAs; therefore, differences in FADS1-2-3 activity are
expected to be observed in triglycerides with a large
number of double bonds and carbon atoms. Indeed, the
GGM concords with established biochemistry since this
locus is associated with triglycerides (TG) 56:6, 56:7, and
58:9 but is not associated with triglycerides with fewer
double bonds or carbon atoms. In contrast, it is unclear
why variants in the PNPLA3 locus also have the stron-
gest associations with triglycerides with a relatively
larger number of carbon atoms and double bonds,
namely TG(56:5) and TG(56:6) (see also Fig. 5). One
possible explanation is that significantly associated vari-
ants in the PNPLA3 locus are changing the substrate
specificity so that there is a shift in the relative amounts
of triglycerides that are exported from the liver.
Additionally, the network diagram confirms that
LPL is mainly active on MUFAs in triglyceride spe-
cies. Variants in the LPL locus are significantly associ-
ated with TG(52:2), TG(52:3), TG(53:2), and TG(53:
3), which have a high probability of containing one or
more MUFAs within their fatty acid side chains. Fig-
ure 2 also shows that triglycerides and diglycerides
are predominantly inversely associated with LPL vari-
ants, while triglycerides are positively associated
with patatin-like phospholipase domain containing
protein 3 (PNPLA3) variants. Variants in the LPL
locus are also positively associated with phosphocho-
lines, sphingomyelins, and cholesterol esters, although
the associations for the majority of the lipids in these
subclasses did not reach genome-wide significance.
Fig. 3 Combined network graph summarising genetic associations and a Gaussian graphical model (GGM) relating to levels of individual lipid
species in PROMIS. Nodes representing genetic loci are each labelled with the most likely “causal” gene at that locus according to our functional
annotation (see “Methods” section). In order for an edge to be drawn between a genetic locus and a lipid subclass, there must have been a
minimum of one variant at that locus significantly (P < 8.9 x 10-10) associated with a minimum of one lipid species belonging to that lipid
subclass. Edges between lipid subclasses indicate whether there was either a significant over- (green) or under- (purple) representation (the
magnitude is indicated in the thickness of the edges) of GGM connections between lipid species belonging to different lipid subclasses
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New biological insights into lipid metabolism
Our analysis replicated known associations between
lipids and genetic loci while also further extending what
is known about these loci. We found significant associa-
tions of a wide range of lipids, including [PA(39:1)+H]+,
[PC(35:4)+H]+, and [PE(36:4)+H]+, with variants in the
LIPC locus (Supplementary Figure 7k); and significant
associations of five specific sphingomyelins ([SM(34:0)+
H]+, [SM(40:0)+H]+, [SM(40:1)+H]+, [SM(40:2)+H]+,
and [SM(42:1)+H]+), and with variants in the APOE-C1-
C2-C4 locus (Supplementary Figure 7c). We also identi-
fied significant associations of four further sphingomye-
lins ([SM(32:1)-CH3]
-, [SM(32:1)+H]+, [SM(32:1)+OAc]-,
and [SM(39:1)+H]+) with variants in the SGPP1 locus
(Supplementary Figure 7u). Additionally, we found sig-
nificant associations of nine ceramides ([Cer(40:0)-H]-,
[Cer(40:1)-H]-, [Cer(40:2)-H]-, [Cer(41:0)-H]-, [Cer(41:
1)-H]-, [Cer(41:2)-H]-, [Cer(42:0)-H]-, [Cer(42:1)-H]-,
and [Cer(42:2)-H]-) with variants in the SPTLC3 locus,
which have not previously been reported in relation to
this locus, as well as significant associations with three
phosphatidylcholines and fifteen sphingomyelins (Sup-
plementary Figure 7v).
We also discovered genetic associations with lipids
at PNPLA3 and membrane bound O-acyltransferase
domain containing 7 (MBOAT7) loci that may have
important biological and clinical implications. We
found significant associations of two triglycerides—
[TG(56:6)+NH4]
+ (m/z 924.801) and [TG(56:5)+NH4]
+
(m/z 926.817)—with rs12484809, an intronic variant
in the PNPLA3 locus (Supplementary Figure 7s). We
also found that the lead SNP in the MBOAT7 locus,
rs8736 (chr19:54677189), was associated with a wide
range of phosphatic acids (e.g. [PA(40:5)+OAc]- and
[PA(44:6)+OAc]-), phosphatidylcholines (e.g. [PC(36:
6)+OAc]- and [PC(42:11)+OAc]-), and phosphoinosi-
tols (e.g. [PI(34:1)-H]-) (Supplementary Figure 7m).
We undertook further investigation of a related nonsy-
nonymous PNPLA3 variant that is in moderate LD (r2 =
0.695), rs738409 (p.Ile148Met), to study the associations
Fig. 4 Combined network graph summarising genetic associations and a Gaussian graphical model (GGM) relating to levels of individual
triglycerides in PROMIS. Nodes representing genetic loci are each labelled with the most likely “causal” gene at that locus according to our
functional annotation (see “Methods” section). In order for an edge to be drawn between a genetic locus and a triglyceride, there must have
been a minimum of one variant at that locus significantly (P < 8.9 x 10-10) associated with at least one triglyceride. Edges between triglycerides
indicate whether there was either a significant over- (green) or under- (purple) representation, with the magnitude indicated by the thickness of
the edges
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of lipids with PNPLA3 in greater detail, including those
that did not reach genome-wide significance. We fo-
cused on this variant rather than rs12484809 because
I148M is already known to be associated with total
triglycerides [33] and has been extensively charac-
terised in previous genetic and functional analyses,
and therefore is more likely to have potential clinical
applications. As shown in Fig. 5a, the PNPLA3
I148M allele was associated with increased levels of
lipids of higher carbon number and double-bond
content, and consistently, with decreased levels of
lipids of lower carbon number and double-bond con-
tent. There were also significant differences between
the mean levels of the triglycerides TG(57:10),
TG(46:0), and TG(56:6) between individuals stratified
by PNPLA3 I148M genotype (Fig. 5b–d).
Discussion
Based on a comprehensive analysis of genetic influences
on 340 human blood lipids assayed in 5662 individuals
from Pakistan, we identified 253 significant associations
between 181 lipids and 24 genetic loci. Additionally, in
our analysis of 399 lipids in 13,814 British blood donors,
we identified significant associations between 244 lipids
and 38 independent loci. The majority of genetic regions
associated with lipids in PROMIS were also found in
INTERVAL; those that did not replicate may be due to
the increased sample size in INTERVAL which gave a
substantial boost in power. These findings suggest that
genetically determined aspects of lipid metabolism are
broadly similar in individuals of South Asian and Euro-
pean ancestry, and that DIHRMS can reliably capture
differences in lipid levels across diverse populations.
Fig. 5 Association of lipids in PROMIS with PNPLA3 and differences in levels of triglycerides by genotype. a Association of G allele of rs738409 in
PNPLA3 locus with levels of various lipids in PROMIS. The black lines denote 95% confidence intervals. Difference in levels of triglycerides in
PROMIS by genotype: b [TG(57:10)+NH4]
+ (m/z 930.754), c [TG(46:0)+NH4]
+ (m/z 796.7393), and d [TG(56:6)+NH4]
+ (m/z 924.801). P values are for
ANOVA test of difference in mean levels of triglycerides by genotype
Harshfield et al. BMC Medicine          (2021) 19:232 Page 12 of 17
There were six genetic loci specific to lipid levels in
PROMIS: ANGPTL3, UGT8, PCTP, C19orf80, XBP1,
and GAL3ST1. Angiopoietin-like 3 (ANGPTL3) is in-
volved in the regulation of lipid and glucose metabolism.
SNPs in the ANGPTL3 region have previously been
shown to be associated with major lipids, including
LDL-C and total cholesterol [34, 35]. In PROMIS,
rs6657050, an intronic variant in the ANGPTL3 locus,
was significantly associated with [PI(36:2)-H]- (m/z
861.5498) (Supplementary Figure 7a).
UDP glycosyltransferase 8 (UGT8) catalyses the trans-
fer of galactose to ceramide, a key enzymatic step in the
biosynthesis of galactocerebrosides, which are abundant
sphingolipids of the myelin membrane of the central and
peripheral nervous system. In PROMIS, rs28870381, an
intergenic variant in UGT8, was associated with [PG(32:
1)+OAc]- (m/z 779.5078) (Supplementary Figure 7w).
Phosphatidylcholine transfer protein (PCTP) catalyses
the transfer of phosphatidylcholines between membranes
and is involved in lipid binding. Through regulation of
plasma lipid concentrations, it may also modulate the
development of atherosclerosis [36]. In PROMIS,
rs11079173, an intronic variant in the PCTP locus, was
associated with [PA(40:5)+OAc]- (m/z 809.5337) (Sup-
plementary Figure 7p).
C19orf80, also known as angiopoietin-like 8 (ANGP
TL8), is involved in the regulation of serum triglyceride
levels and is associated with major lipids including
HDL-C and triglycerides [35]. In PROMIS, rs8101801,
an intronic variant in the C19orf80 locus, was signifi-
cantly associated with [PI(38:4)-H]- (m/z 885.5498) (Sup-
plementary Figure 7d).
Galactose-3-O-sulfotransferase 1 (GAL3ST1) catalyses
the sulfation of membrane glycolipids and the synthesis of
galactosylceramide sulfate, a major lipid component of the
myelin sheath. In PROMIS, rs2267161, a missense variant
in the GAL3ST1 locus, was associated with [PG(32:1)+
OAc]- (m/z 779.5078) (Supplementary Figure 7i).
X-box binding protein 1 (XBP1) functions as a tran-
scription factor during endoplasmic reticulum stress by
regulating the unfolded protein response. It is also a
major regulator of the unfolded protein response in
obesity-induced insulin resistance and T2D for the man-
agement of obesity and diabetes prevention. Recent
studies have shown that compounds targeting the XBP1
pathway are a potential approach for the treatment of
metabolic diseases [37]. In addition, XBP1 protein ex-
pression, which is induced in the liver by a high carbo-
hydrate diet, is directly involved in fatty acid synthesis
through de novo lipogenesis. Therefore, compounds that
inhibit XBP1 activation may also be useful for the treat-
ment of NAFLD [38]. In PROMIS, rs71661463, an in-
tronic variant for which XBP1 is the candidate causal
gene, was associated with [SM(37:1)+H]+ (m/z 745.6216)
(Supplementary Figure 7x). Recent research across many
species has shown that XBP1 is a transcription factor
regulating hepatic lipogenesis. In mice, hepatic XBP1 ex-
pression is regulated by proopiomelanocortin (POMC)
during sensory food perception and coincides with
changes in the lipid composition of the liver with in-
creases in PCs and PEs [39]. Although previous studies
have shown direct links between XBP1 and overall lipid
metabolism, this is the first time a genetic association
has been reported between XBP1 and lipid metabolites
in humans, affecting sphingomyelins, PCs, and PEs (Sup-
plementary Figure 7x).
Our findings for the PNPLA3 and MBOAT7 loci were
also notable. PNPLA3 is a multifunctional enzyme that
encodes a triacylglycerol lipase, which mediates triacyl-
glycerol hydrolysis in adipocytes and has acylglycerol O-
acyltransferase activity. The relationship between
rs738409, a nonsynonymous variant (p.Ile148Met) in the
PNPLA3 gene, and non-alcoholic fatty liver disease
(NAFLD) has been well established [40]. This variant
has been shown to impair triglyceride hydrolysis in the
liver and secretion of triglyceride-rich very low-density
lipoproteins, leading to the altered fatty acid compos-
ition of liver triglycerides, and is also associated with re-
duced risk of CHD [41] and increased risk of type 2
diabetes (T2D) [42]. This suggests that targeting hepatic
pathways to reduce cardiovascular risk may be complex,
despite the clustering of cardiovascular and hepatic dis-
eases in people with metabolic syndrome. Our analysis
offers granularity to the previously identified total trigly-
ceride associations with PNPLA3 by identifying two spe-
cific triglyceride species that may have a role in PNPLA3
function.
MBOAT7, which contributes to the regulation of free
arachidonic acid in the cell through the remodelling of
phospholipids, was reported as being associated with the
metabolite 1-arachidonoylglycerophosphoinositol in a
previous mGWAS [19] (known as [PI(36:4)-H]- in our
study), but we found that the lead SNP in this locus,
rs8736 (chr19:54677189), was also associated with a wide
range of phosphatic acids, phosphatidylcholines, phos-
phatidylethanolamines, and phosphoinositols (Supple-
mentary Figure 7m). Several studies have shown that
MBOAT7 (also known as lysophosphatidylinositol-
acyltransferase 1 [LPIAT1]) is responsible for the trans-
fer of arachidonoyl-CoA to lysophosphoinositides [43].
The creation of MBOAT7-deficient macrophages show a
decreased level of [PI(38:4)-H]- and an increase of
[PI(34:1)-H]- as well as [PI(40:5)-H]- [44]. The T allele of
rs8736, a 3’ UTR SNP, shows a similar shift in the phos-
phatidylinositol metabolism. Our work shows that this
SNP is also strongly associated with [PI(38:3)+OAc]- (m/
z 947.5866), which is likely to be the dihomo-gamma
linoleic acid (20:3n6)-containing phosphoinositol. None
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of the papers testing the substrate specificity of
MBOAT7 have included dihomo-gamma linoleic acid or
[PI(38:3)+OAc]- in their analysis. Thus, we provide novel
evidence in humans that there is an association between
MBOAT7 activity and circulating phosphatidylinositols,
a finding that requires further replication.
Our network diagram helped identify sphingomyelins
that were associated exclusively with four loci that were
not associated with any other lipid subclasses: GCKR,
SGPP1, MLXIPL, and XBP1. Sphingomyelins have previ-
ously been shown to be associated with SGPP1 [45], but
the associations of sphingomyelins with these other
three loci are reported here for the first time. GCKR has
been shown to be associated with total cholesterol and
triglycerides (see Fig. 2) and has also been associated
with the plasma phospholipid fraction fatty acids 16:0
and 16:1 [46, 47]; most lipids that we found to be associ-
ated with GCKR (Supplementary Figure 7j) are likely to
contain these particular fatty acids. It has been suggested
that the glucokinase receptor, encoded by GCKR, affects
the production of malonyl-CoA, an important substrate
for de novo lipogenesis [46]. To a similar extent, there is
a known relation between MLXIPL and carbohydrate
and lipid metabolism. MLXIPL is a transcription factor
affecting carbohydrate response element-binding protein
(CREBP) and therefore also plays a role in lipogenesis.
Although both these genes have previously been linked
to lipogenesis, we discovered that genetic variation at
genes involved in the regulation of lipogenesis has been
implicated in altering sphingomyelin concentrations.
The network diagram also helped recapitulate known
biological relationships between lipids. As we established
in our previous analysis [7], the number of significant
partial correlations between lipids of different subclasses
was significantly higher than would be expected due to
chance alone. This analysis further showed that genes
that were significantly associated with lipids of a particu-
lar subclass regulated all of the lipids within the subclass
in a similar manner. Therefore, the total concentrations
of a given lipid class associated with a genetic locus are
less affected by the proportion of fatty acids present in
those lipid species.
In summary, our analyses resulted in the following
new insights in an understudied South Asian population:
(1) we established that decreased levels of sphingomye-
lins are associated with genetically lower LPL activity; (2)
we revealed a wide range of glycerophospholipids that
are associated with variants in the MBOAT7 locus; (3)
we identified several new associations of phosphatic
acids, phosphocholines, and phosphoethanolamines with
variants in the LIPC region; (4) we found several novel
associations of sphingomyelins and phosphocholines
with variants in the APOE-C1-C2-C4 cluster; (5) we dis-
covered four new associations of sphingomyelins with
variants in the SGPP1 locus; and (6) we found several
previously unreported associations of phosphocholines,
sphingomyelins, and ceramides with variants in the
SPTLC3 locus. These findings can help further the iden-
tification of novel therapeutic targets for prevention and
treatment.
Our investigation into the genetic influences of lipids
has several strengths. First, the research involved partici-
pants from a population cohort in Pakistan, thereby en-
hancing the scientific understanding of lipid associations
in this understudied population, and we compared the
findings with a typical Western population of British
blood donors using the same lipid-profiling platform.
Second, the analysis was based on a relatively large data-
set of 5662 participants from Pakistan and an even larger
cohort of 13,814 individuals from the UK, thereby in-
creasing statistical power to detect associations. Third,
our mGWAS was performed in individuals free from
established MI at baseline in PROMIS and healthy blood
donors in INTERVAL, which reduces spurious associa-
tions due to the disease state or potential treatments. Fi-
nally, our newly developed open-profiling lipidomics
platform was utilised to provide detailed lipid profiles,
with a wider coverage of lipids than most other high-
throughput profiling methods [7], which improved our
ability to detect novel associations and our understand-
ing of the detailed effects of known lipid loci at the level
of individual lipid species.
Nevertheless, our study has several technical limita-
tions. To enable the rapid and robust lipid profiling of
such a large number of samples, we employed DIHRMS.
Despite the advantages of this platform, it is unable to
distinguish isobaric lipids. This means that different lipid
species can contribute to the same signal; for instance,
[PC(32:1)+H]+ and [PE(35:1)+H]+ both have the same
molecular formula (C40H77NO8P) and will both contrib-
ute to the signal of m/z 732.5541. Furthermore, even
[PC(32:1)+H]+ consists of both PC(16:0/16:1) and PC(14:
0/18:1). These limitations are discussed in detail in our
previous methodological paper on this platform [7],
while the relevance of using these aggregate of signals in
metabolic studies has been shown by other studies [45].
Further work, with improved analytical resolution, will
enable further pinpointing of the relevant lipids to the
identified loci.
The cohorts included in our analysis also have several
potential limitations. First, possible selection biases arise
from the case-control design of PROMIS, although this
was minimised by the recruitment of controls from pa-
tients, visitors of patients attending out-patient clinics,
and unrelated visitors of cardiac patients. Second, serum
samples in PROMIS were stored in freezers at −80°C for
between 2 and 8 years before aliquots were taken for the
lipidomics measurements, which we accounted for by
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adjusting the analyses by the number of years that the
samples had been stored. Although residual confounding
and deterioration of lipid profiles may still exist, such
deterioration is unlikely to have been related to geno-
type. Third, a majority (76%) of PROMIS participants
had not fasted prior to blood draw, and a small propor-
tion of participants (7%) had reportedly fasted for an un-
known duration. Recent food consumption may have
had significant effects on lipid levels and influenced the
results. Our analyses adjusted for fasting status although
we lacked statistical power to stratify by fasting status.
Fourth, PROMIS participants were recruited from mul-
tiple centres in urban Pakistan [7], but it is unclear
whether the findings from this study would be
generalizable to individuals living in rural villages and
other parts of Pakistan, or in other countries in South
Asia. However, the confirmatory analysis in INTERVAL,
in which we identified significant associations with lipids
for the majority of the genetic loci found in PROMIS,
helps strengthen the argument that these findings are
generalizable. Additionally, many of the lipids were asso-
ciated with known genetic regions such as APOA5-C3
and FADS1-2-3, which have already been shown to be
associated with multiple lipids in other Western popula-
tions, further strengthening the validity of the findings
from this analysis. Finally, although two-sample Mendel-
ian randomization approaches to make causal inferences
about the association of lipids with CHD risk factors and
disease outcomes hold great promise in the lipidomics
arena [48], extensive pleiotropy made it too difficult to
disentangle the findings and we chose not to pursue this
avenue. Therefore, although especially stringent proce-
dures were followed, highly conservative cut-offs were
used to determine statistical significance, and rigorous
pre-analysis and post-analysis quality control steps were
performed, there is still a possibility that some of the
findings were false positives that arose due to artefacts
rather than being true signals. Additional analyses in
other populations using the DIHRMS lipidomics plat-
form would be helpful to further replicate our findings.
Moreover, the identified pathways and proposed mo-
lecular mechanisms require validation through func-
tional analyses in model organisms and humans.
Further research will be able to leverage these lipidomics
results in combination with whole-genome and whole-
exome sequencing performed in PROMIS and INTER-
VAL to help understand the consequences of loss-of-
function mutations identified in these participants [49].
Conclusions
In conclusion, this article presents the results from a
comprehensive analysis of genetic influences on human
blood lipids in South Asians with a comparative analysis
in the UK. Our findings strengthen and expand the
knowledge base for understanding the genetic determi-
nants of lipids and their association with cardiometa-
bolic disease-related loci. These findings have important
implications for the identification of novel therapeutic
targets and advancement of mechanistic understanding
of metabolic pathways that may lead to the onset of
chronic diseases and lipid-related abnormalities.
Abbreviations
CHD: Coronary heart disease; CVD: Cardiovascular disease;
DHA: Docosahexaenoic acid; DIHRMS: Direct infusion high-resolution mass
spectrometry; FDR: False discovery rate; GGM: Gaussian Graphical Model;
HWE: Hardy-Weinberg Equilibrium; MAF: Minor allele frequency;
MI: Myocardial infarction; m/z: Mass-charge ratio; NAFLD: Non-alcoholic fatty
liver disease; PROMIS: Pakistan Risk of Myocardial Infarction Study;
PUFA: Polyunsaturated fatty acid; SD: Standard deviation; SNP: Single
nucleotide polymorphism; T2D: Type 2 diabetes; QC: Quality control;
QTL: Quantitative trait loci
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12916-021-02087-1.
Additional file 1. Supplementary Methods; Supplementary Figures 1-8.
Additional file 2. Supplementary Tables 1-18.
Additional file 3. Supplementary Figure 1 (high resolution).
Acknowledgements
The authors would like to thank Michael Inouye for his helpful comments on
an earlier version of the manuscript.
Authors’ contributions
E.L.H., J.D., D.Sa., J.L.G., and A.K. conceived and designed the study. J.D. and
D.Sa. are principal investigators of PROMIS. A.M.W., J.L.G., and A.K. jointly
supervised the research. A.K. generated the lipidomics data. E.L.H. and A.K.
processed the lipidomics data. E.L.H. performed the bioinformatics and
statistical analyses. E.B.F., D.St., D.S.P., D.Z., R.M.Y.O., A.S.B., A.M.W., J.L.G., and
A.K. contributed important intellectual content to the study and manuscript.
E.L.H., A.S.B., A.M.W., J.L.G., and A.K. were involved in drafting the manuscript.
The authors read and approved the final manuscript.
Funding
PROMIS: Fieldwork, genotyping, and standard clinical chemistry assays in
PROMIS were principally supported by grants awarded to the University of
Cambridge from the British Heart Foundation (SP/09/002; RG/13/13/30194),
the UK Medical Research Council (G0800270; MR/L003120/1), the Wellcome
Trust, the EU Framework 6–funded Bloodomics Integrated Project, Pfizer,
Novartis, and Merck.
INTERVAL: Participants in the INTERVAL randomised controlled trial were
recruited with the active collaboration of NHS Blood and Transplant England
(http://www.nhsbt.nhs.uk), which has supported fieldwork and other
elements of the trial. DNA extraction and genotyping were co-funded by the
National Institute for Health Research (NIHR), the NIHR BioResource (http://
bioresource.nihr.ac.uk), and the NIHR Cambridge Biomedical Research Centre
at the Cambridge University Hospitals NHS Foundation Trust. The academic
coordinating centre for INTERVAL was supported by core funding from NIHR
Blood and Transplant Research Unit in Donor Health and Genomics (NIHR
BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British
Heart Foundation (SP/09/002, RG/13/13/30194; RG/18/13/33946), and the
NIHR Cambridge Biomedical Research Centre at the Cambridge University
Hospitals NHS Foundation Trust. A complete list of the investigators and con-
tributors to the INTERVAL trial is provided in reference [50]. The academic co-
ordinating centre would like to thank blood donor staff and blood donors
for participating in the INTERVAL trial. The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR, or the Department
of Health and Social Care.
Harshfield et al. BMC Medicine          (2021) 19:232 Page 15 of 17
This work was supported by Health Data Research UK, which is funded by
the UK Medical Research Council, Engineering and Physical Sciences
Research Council, Economic and Social Research Council, Department of
Health and Social Care (England), Chief Scientist Office of the Scottish
Government Health and Social Care Directorates, Health and Social Care
Research and Development Division (Welsh Government), Public Health
Agency (Northern Ireland), British Heart Foundation, and Wellcome.
D.S.P. and D.St. are funded by the Wellcome Trust (105602/Z/14/Z). J.L.G. and
A.K. are funded by the UK Medical Research Council under the Lipid
Dynamics and Regulation supplementary grant (MC_PC_13030) and Lipid
Programming and Signalling program grant (MC_UP_A090_1006) and
Cambridge Lipidomics Biomarker Research Initiative (G0800783). A.K. also
gratefully acknowledges funding from the NIHR Cambridge Biomedical
Research Centre at the Cambridge University Hospitals NHS Foundation Trust
(IS-BRC-1215-20014).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
PROMIS: The institutional review board at the Center for Non-Communicable
Diseases in Karachi, Pakistan, approved the study (IRB: 00007048,
IORG0005843, FWAS00014490), and all participants gave informed consent,
including for use of samples in genetic, biochemical, and other analyses.
INTERVAL: Participants gave electronic informed consent. The National




E.B.F. and D.Z. are employees and shareholders of Pfizer, Inc. J.D. has received
research funding from the British Heart Foundation, the National Institute for
Health Research Cambridge Comprehensive Biomedical Research Centre, the
Bupa Foundation, diaDexus, the European Research Council, the European
Union, the Evelyn Trust, the Fogarty International Centre, GlaxoSmithKline,
Merck, the National Heart, Lung, and Blood Institute, the National Institute for
Health Research [Senior Investigator Award], the National Institute of
Neurological Disorders and Stroke, NHS Blood and Transplant, Novartis,
Pfizer, the UK Medical Research Council, and the Wellcome Trust. J.L.G. has
received funding from Agilent, Waters, GlaxoSmithKline, Medimmune,
Unilever, AstraZeneca, the Medical Research Council, the Biotechnology and
Biological Sciences Research Council, the National Institutes of Health, the
British Heart Foundation, and the Wellcome Trust. D.Sa. has received funding
from Pfizer, Regeneron Pharmaceuticals, Genentech, and Eli Lilly. All other
authors declare no competing interests.
Author details
1British Heart Foundation Cardiovascular Epidemiology Unit, Department of
Public Health and Primary Care, University of Cambridge, Cambridge CB1
8RN, UK. 2Stroke Research Group, Department of Clinical Neurosciences,
University of Cambridge, Cambridge CB2 0QQ, UK. 3Internal Medicine
Research Unit, Pfizer Worldwide Research, Development and Medical,
Cambridge, Massachusetts 02139, USA. 4British Heart Foundation Centre of
Research Excellence, University of Cambridge, Cambridge CB2 0QQ, UK.
5National Institute for Health Research Blood and Transplant Research Unit in
Donor Health and Genomics, University of Cambridge, Cambridge CB1 8RN,
UK. 6National Institute for Health Research Cambridge Biomedical Research
Centre, University of Cambridge and Cambridge University Hospitals,
Cambridge CB2 0QQ, UK. 7Health Data Research UK Cambridge, Wellcome
Genome Campus and University of Cambridge, Cambridge CB10 1SA, UK.
8Department of Human Genetics, Wellcome Sanger Institute, Hinxton CB10
1SA, UK. 9Inflammation and Immunology, Pfizer Worldwide Research,
Development and Medical, 10785 Berlin, Germany. 10Center for
Non-Communicable Diseases, Karachi 75300, Pakistan. 11National Institute of
Cardiovascular Diseases, Karachi 75510, Pakistan. 12Punjab Institute of
Cardiology, Lahore 42000, Pakistan. 13Karachi Institute of Heart Diseases,
Karachi 75950, Pakistan. 14Red Crescent Institute of Cardiology, Hyderabad
71500, Pakistan. 15Faisalabad Institute of Cardiology, Faisalabad 38000,
Pakistan. 16Department of Biostatistics & Epidemiology, University of
Pennsylvania, Philadelphia, Pennsylvania 19104, USA. 17Department of
Biochemistry and Cambridge Systems Biology Centre, University of
Cambridge, Cambridge CB2 1GA, UK. 18Section of Biomolecular Medicine,
Division of Systems Medicine, Department of Metabolism, Digestion, and
Reproduction, Imperial College London, London SW7 2AZ, UK. 19Core
Metabolomics and Lipidomics Laboratory, National Institute for Health
Research, Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK.
Received: 25 September 2020 Accepted: 4 August 2021
References
1. Griffin JL, Atherton H, Shockcor J, Atzori L. Metabolomics as a tool for
cardiac research. Nat Rev Cardiol. 2011;8(11):630–43. https://doi.org/10.1038/
nrcardio.2011.138.
2. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al.
Human demographic history impacts genetic risk prediction across diverse
populations. Am J Hum Genet. 2017;100(4):635–49. https://doi.org/10.1016/
J.AJHG.2017.03.004.
3. Jha P, McDevitt MT, Halilbasic E, Williams EG, Quiros PM, Gariani K, et al.
Genetic regulation of plasma lipid species and their association with
metabolic phenotypes. Cell Syst. 2018;6(6):709–21. https://doi.org/10.1016/j.
cels.2018.05.009.
4. Jha P, McDevitt MT, Gupta R, Quiros PM, Williams EG, Gariani K, et al.
Systems analyses reveal physiological roles and genetic regulators of liver
lipid species. Cell Syst. 2018;6(6):722–33. https://doi.org/10.1016/J.CELS.2018.
05.016.
5. Saleheen D, Zaidi M, Rasheed A, Ahmad U, Hakeem A, Murtaza M, et al. The
Pakistan Risk of Myocardial Infarction Study: a resource for the study of
genetic, lifestyle and other determinants of myocardial infarction in South
Asia. Eur J Epidemiol. 2009;24(6):329–38. https://doi.org/10.1007/s10654-009-
9334-y.
6. Howson JMM, Zhao W, Barnes DR, Ho WK, Young R, Paul DS, et al. Fifteen
new risk loci for coronary artery disease highlight arterial-wall-specific
mechanisms. Nat Genet. 2017;49(7):1113–9. https://doi.org/10.1038/ng.3874.
7. Harshfield EL, Koulman A, Ziemek D, Marney L, Fauman EB, Paul DS, et al.
An unbiased lipid phenotyping approach to study the genetic determinants
of lipids and their association with coronary heart disease risk factors. J
Proteome Res. 2019;18(6):2397–410. https://doi.org/10.1021/acs.jproteome.
8b00786.
8. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD,
DePristo MA, Durbin RM, et al. An integrated map of genetic variation from
1,092 human genomes. Nature. 2012;491:56–65. doi:https://doi.org/10.1038/
nature11632.
9. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype
imputation method for the next generation of genome-wide association
studies. PLoS Genet. 2009;5(6):e1000529. https://doi.org/10.1371/journal.
pgen.1000529.
10. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The allelic
landscape of human blood cell trait variation and links to common
complex disease. Cell. 2016;167(5):1415–29. https://doi.org/10.1016/j.cell.201
6.10.042.
11. Marchini J, Howie B. Genotype imputation for genome-wide association
studies. Nat Rev Genet. 2010;11(7):499–511. https://doi.org/10.1038/nrg2796.
12. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics. 2010;26(17):2190–1. https://
doi.org/10.1093/bioinformatics/btq340.
13. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsson BJ, Finucane HK, Salem RM,
et al. Efficient Bayesian mixed-model analysis increases association power in
large cohorts. Nat Genet. 2015;47(3):284–90. https://doi.org/10.1038/ng.3190.
14. Stacey D, Fauman EB, Ziemek D, Sun BB, Harshfield EL, Wood AM, et al.
ProGeM: a framework for the prioritization of candidate causal genes at
molecular quantitative trait loci. Nucleic Acids Res. 2019;47(1):e3. https://doi.
org/10.1093/nar/gky837.
15. Opgen-Rhein R, Strimmer K. From correlation to causation networks: a
simple approximate learning algorithm and its application to high-
dimensional plant gene expression data. BMC Syst Biol. 2007;1(1):37. https://
doi.org/10.1186/1752-0509-1-37.
Harshfield et al. BMC Medicine          (2021) 19:232 Page 16 of 17
16. Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ. Gaussian graphical modeling
reconstructs pathway reactions from high-throughput metabolomics data.
BMC Syst Biol. 2011;5(1):21. https://doi.org/10.1186/1752-0509-5-21.
17. Gobbi A, Iorio F, Dawson KJ, Wedge DC, Tamborero D, Alexandrov LB, et al.
Fast randomization of large genomic datasets while preserving alteration
counts. Bioinformatics. 2014;30(17):i617–23. https://doi.org/10.1093/
bioinformatics/btu474.
18. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al.
Integration of biological networks and gene expression data using Cytoscape.
Nat Protoc. 2007;2(10):2366–82. https://doi.org/10.1038/nprot.2007.324.
19. Shin S-Y, Fauman EB, Petersen A-K, Krumsiek J, Santos R, Huang J, et al. An
atlas of genetic influences on human blood metabolites. Nat Genet. 2014;
46(6):543–50. https://doi.org/10.1038/ng.2982.
20. Chasman DI, Pare G, Mora S, Hopewell JC, Peloso G, Clarke R, et al. Forty-
three loci associated with plasma lipoprotein size, concentration, and
cholesterol content in genome-wide analysis. PLoS Genet. 2009;5(11):
e1000730. https://doi.org/10.1371/journal.pgen.1000730.
21. Rueedi R, Ledda M, Nicholls AW, Salek RM, Marques-Vidal P, Morya E, et al.
Genome-wide association study of metabolic traits reveals novel gene-
metabolite-disease links. PLoS Genet. 2014;10(2):e1004132. https://doi.org/1
0.1371/journal.pgen.1004132.
22. Teslovich TM, Kim DS, Yin X, Stančáková A, Jackson AU, Wielscher M, et al.
Identification of seven novel loci associated with amino acid levels using
single-variant and gene-based tests in 8545 Finnish men from the METSIM
study. Hum Mol Genet. 2018;27(9):1664–74. https://doi.org/10.1093/hmg/
ddy067.
23. Demirkan A, van Duijn CM, Ugocsai P, Isaacs A, Pramstaller PP, Liebisch G,
et al. Genome-wide association study identifies novel loci associated with
circulating phospho- and sphingolipid concentrations. PLoS Genet. 2012;
8(2):e1002490. https://doi.org/10.1371/journal.pgen.1002490.
24. Tabassum R, Rämö JT, Ripatti P, Koskela JT, Kurki M, Karjalainen J, et al.
Genetic architecture of human plasma lipidome and its link to
cardiovascular disease. Nat Commun. 2019;10(1):4329. https://doi.org/10.103
8/s41467-019-11954-8.
25. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al.
Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73–
9. https://doi.org/10.1038/s41586-018-0175-2.
26. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA,
et al. ApoAV reduces plasma triglycerides by inhibiting very low density
lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein
lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279(27):27941–7.
https://doi.org/10.1074/jbc.M403240200.
27. Ariza MJ, Sanchez-Chaparro MA, Baron FJ, Hornos AM, Calvo-Bonacho E, Rioja
J, et al. Additive effects of LPL, APOA5 and APOE variant combinations on
triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-
study. BMC Med Genet. 2010;11(1):66. https://doi.org/10.1186/1471-2350-11-66.
28. Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, Ban MR, et al.
Excess of rare variants in genes identified by genome-wide association
study of hypertriglyceridemia. Nat Genet. 2010;42(8):684–7. https://doi.org/1
0.1038/ng.628.
29. Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I,
Arellano-Campos O, et al. Genomic study in Mexicans identifies a new locus
for triglycerides and refines European lipid loci. J Med Genet. 2013;50(5):
298–308. https://doi.org/10.1136/jmedgenet-2012-101461.
30. De Castro-Orós I, Cenarro A, Tejedor MT, Baila-Rueda L, Mateo-Gallego R,
Lamiquiz-Moneo I, et al. Common genetic variants contribute to primary
hypertriglyceridemia without differences between familial combined
hyperlipidemia and isolated hypertriglyceridemia. Circ Cardiovasc Genet.
2014;7(6):814–21. https://doi.org/10.1161/CIRCGENETICS.114.000522.
31. Eiden M, Koulman A, Hatunic M, West JA, Murfitt S, Osei M, et al.
Mechanistic insights revealed by lipid profiling in monogenic insulin
resistance syndromes. Genome Med. 2015;7(1):63. https://doi.org/10.1186/
s13073-015-0179-6.
32. Sanders FWB, Acharjee A, Walker C, Marney L, Roberts LD, Imamura F, et al.
Hepatic steatosis risk is partly driven by increased de novo lipogenesis
following carbohydrate consumption. Genome Biol. 2018;19(1):79. https://
doi.org/10.1186/s13059-018-1439-8.
33. Tang CS, Zhang H, Cheung CY, Xu M, Ho JC, Zhou W, et al. Exome-wide
association analysis reveals novel coding sequence variants associated with
lipid traits in Chinese. Nat Commun. 2015;6(1):10206. https://doi.org/10.103
8/ncomms10206.
34. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso
GM, Gustafsson S, et al. Discovery and refinement of loci associated with lipid
levels. Nat Genet. 2013;45:1274–83. doi:https://doi.org/10.1038/ng.2797.
35. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, et al.
Genetics of blood lipids among ~300,000 multi-ethnic participants of the
Million Veteran Program. Nat Genet. 2018;50(11):1514–23. https://doi.org/1
0.1038/s41588-018-0222-9.
36. Wang WJ, Baez JM, Maurer R, Dansky HM, Cohen DE. Homozygous disruption
of Pctp modulates atherosclerosis in apolipoprotein E-deficient mice. J Lipid
Res. 2006;47(11):2400–7. https://doi.org/10.1194/jlr.M600277-JLR200.
37. Piperi C, Adamopoulos C, Papavassiliou AG. XBP1: a pivotal transcriptional
regulator of glucose and lipid metabolism. Trends Endocrinol Metab. 2016;
27(3):119–22. https://doi.org/10.1016/j.tem.2016.01.001.
38. Glimcher LH, Lee AH. From sugar to fat: how the transcription factor XBP1
regulates hepatic lipogenesis. Ann N Y Acad Sci. 2009;1173(Suppl):E2–9.
https://doi.org/10.1111/j.1749-6632.2009.04956.x.
39. Brandt C, Nolte H, Henschke S, Engström Ruud L, Awazawa M, Morgan DA,
et al. Food perception primes hepatic ER homeostasis via melanocortin-
dependent control of mTOR activation. Cell. 2018;175:1321-1335.e20. doi:
https://doi.org/10.1016/J.CELL.2018.10.015.
40. Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty
liver disease: a comprehensive review. World J Gastroenterol. 2015;21(39):
11088–111. https://doi.org/10.3748/wjg.v21.i39.11088.
41. Simons N, Isaacs A, Koek GH, Kuc S, Schaper NC, Brouwers MC. PNPLA3, TM6SF2,
and MBOAT7 genotypes and coronary artery disease. Gastroenterology. 2017;
152(4):912–3. https://doi.org/10.1053/j.gastro.2016.12.020.
42. Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, et al.
Refining the accuracy of validated target identification through coding
variant fine-mapping in type 2 diabetes. Nat Genet. 2018;50(4):559–71.
https://doi.org/10.1038/s41588-018-0084-1.
43. Gijón MA, Riekhof WR, Zarini S, Murphy RC, Voelker DR. Lysophospholipid
acyltransferases and arachidonate recycling in human neutrophils. J Biol
Chem. 2008;283(44):30235–45. https://doi.org/10.1074/jbc.M806194200.
44. Takemasu S, Ito M, Morioka S, Nigorikawa K, Kofuji S, Takasuga S, et al.
Lysophosphatidylinositol-acyltransferase-1 is involved in cytosolic Ca2+
oscillations in macrophages. Genes to Cells. 2019;24(5):366–76. https://doi.
org/10.1111/gtc.12681.
45. Draisma HH, Pool R, Kobl M, Jansen R, Petersen AK, Vaarhorst AA, et al.
Genome-wide association study identifies novel genetic variants
contributing to variation in blood metabolite levels. Nat Commun. 2015;6(1):
7208. https://doi.org/10.1038/ncomms8208.
46. Wu JH, Lemaitre RN, Manichaikul A, Guan W, Tanaka T, Foy M, et al.
Genome-wide association study identifies novel loci associated with
concentrations of four plasma phospholipid fatty acids in the de novo
lipogenesis pathway: results from the Cohorts for Heart and Aging Research
in Genomic Epidemiology (CHARGE) consortiu. Circ Cardiovasc Genet. 2013;
6(2):171–83. https://doi.org/10.1161/CIRCGENETICS.112.964619.
47. Hu Y, Tanaka T, Zhu J, Guan W, Wu JHY, Psaty BM, et al. Discovery and fine-
mapping of loci associated with MUFAs through trans-ethnic meta-analysis
in Chinese and European populations. J Lipid Res. 2017;58(5):974–81.
https://doi.org/10.1194/jlr.P071860.
48. Burgess S, Harshfield E. Mendelian randomization to assess causal effects of
blood lipids on coronary heart disease: lessons from the past and
applications to the future. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):
124–30. https://doi.org/10.1097/MED.0000000000000230.
49. Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, Khetarpal SA, et al.
Human knockouts and phenotypic analysis in a cohort with a high rate of
consanguinity. Nature. 2017;544(7649):235–9. https://doi.org/10.1038/nature22034.
50. Di Angelantonio E, Thompson S, Kaptoge S, Moore C, Walker M, Armitage J,
et al. Efficiency and safety of varying the frequency of whole blood
donation (INTERVAL): a randomised trial of 45 000 donors. Lancet. 2017;
390(10110):2360–71. https://doi.org/10.1016/S0140-6736(17)31928-1.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Harshfield et al. BMC Medicine          (2021) 19:232 Page 17 of 17
